71% of ALL Patients Achieved Complete Tumor Remission on Gilead, Kite's CAR-T Therapy By Sam | December 11, 2017 The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta. Source: BioSpace Posted in BioPharma